Form 4: Monopar Therapeutics Director Exercises Options, Sells Shares for $672,000

Monopar Therapeutics Director Christopher M. Starr exercised stock options and subsequently sold 16,800 shares of common stock for approximately $672,000.

Summary

• Director Christopher M. Starr exercised 16,800 stock options at an exercise price of $0.005 per share on July 14, 2025.
• Simultaneously, 16,800 shares of common stock were sold at a weighted average price of $40.0012 per share on July 14, 2025.
• The total proceeds from the sale of shares amounted to approximately $672,019.
• Following these transactions, Dr. Starr directly holds 5,173 shares of common stock.
• Additionally, 9,880 shares of common stock are indirectly held by the Christopher M. Starr and Sheri L. Starr Revocable Trust, for which Dr. Starr serves as Trustee.
• The exercised options were granted on April 4, 2016, for Dr. Starr's services as a director and were set to expire on April 4, 2026.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While insider selling can sometimes be viewed negatively, this transaction appears to be a standard exercise of options and subsequent sale for liquidity, rather than a signal of lack of confidence, especially given the significant gain realized by the director.

Positives

• Director exercised options, indicating value in the underlying stock at the exercise price.
• Significant personal gain for the director from the option exercise and sale, demonstrating the potential profitability of long-held equity incentives.

Negatives

• Director sold a substantial portion of directly held shares (16,800 shares), which could be interpreted as a reduction in direct exposure to the company's future performance.

Risks

• Insider selling, even if pre-planned, can sometimes be perceived negatively by the market, potentially leading to a decrease in investor confidence.

Future Outlook

N/A

Industry Context

This transaction is a routine insider filing (Form 4) detailing a director's exercise of stock options and subsequent sale of shares. It does not provide broader industry context or trends, but such sales are common for executives and directors managing their personal portfolios and liquidity.

Related Party Transactions

• The indirect ownership of 9,880 shares by the Christopher M. Starr and Sheri L. Starr Revocable Trust constitutes a related party transaction, as Dr. Starr serves as Trustee.

Stakeholder Impact

• Shareholders may observe the director's sale of shares, which could be interpreted in various ways, from a routine liquidity event to a potential signal about future company performance, though the latter is less likely given the nature of option exercise and sale.

Key Dates

Recommendation

Keywords

Monopar Therapeutics, MNPR, SEC Form 4, Insider Trading, Stock Options, Director Stock Sale, Equity Compensation, Christopher M. Starr, Beneficial Ownership